Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters)

Kadri Altundag, Ozden Altundag, Paolo Morandi, Mehmet Gunduz, Natasha M. Tiffany, Emily M. Wersinger, Tomasz (Tom) Beer, Mark Garzotto

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)211-212
Number of pages2
JournalUrology
Volume65
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

zoledronic acid
Neoplasm Proteins
Antineoplastic Combined Chemotherapy Protocols
Piperazines
Imidazoles
Platelet-Derived Growth Factor Receptors
Bone Neoplasms
Pyrimidines
Diphosphonates
Treatment Failure
Palliative Care
Androgens
Prostatic Neoplasms
Adenocarcinoma
Imatinib Mesylate

ASJC Scopus subject areas

  • Urology

Cite this

Altundag, K., Altundag, O., Morandi, P., Gunduz, M., Tiffany, N. M., Wersinger, E. M., ... Garzotto, M. (2005). Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters). Urology, 65(1), 211-212. https://doi.org/10.1016/j.urology.2004.06.005

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters). / Altundag, Kadri; Altundag, Ozden; Morandi, Paolo; Gunduz, Mehmet; Tiffany, Natasha M.; Wersinger, Emily M.; Beer, Tomasz (Tom); Garzotto, Mark.

In: Urology, Vol. 65, No. 1, 01.2005, p. 211-212.

Research output: Contribution to journalArticle

Altundag K, Altundag O, Morandi P, Gunduz M, Tiffany NM, Wersinger EM et al. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters). Urology. 2005 Jan;65(1):211-212. https://doi.org/10.1016/j.urology.2004.06.005
Altundag, Kadri ; Altundag, Ozden ; Morandi, Paolo ; Gunduz, Mehmet ; Tiffany, Natasha M. ; Wersinger, Emily M. ; Beer, Tomasz (Tom) ; Garzotto, Mark. / Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters). In: Urology. 2005 ; Vol. 65, No. 1. pp. 211-212.
@article{6cc0ce27c72e40ec806a2c25af0f8689,
title = "Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters)",
author = "Kadri Altundag and Ozden Altundag and Paolo Morandi and Mehmet Gunduz and Tiffany, {Natasha M.} and Wersinger, {Emily M.} and Beer, {Tomasz (Tom)} and Mark Garzotto",
year = "2005",
month = "1",
doi = "10.1016/j.urology.2004.06.005",
language = "English (US)",
volume = "65",
pages = "211--212",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters)

AU - Altundag, Kadri

AU - Altundag, Ozden

AU - Morandi, Paolo

AU - Gunduz, Mehmet

AU - Tiffany, Natasha M.

AU - Wersinger, Emily M.

AU - Beer, Tomasz (Tom)

AU - Garzotto, Mark

PY - 2005/1

Y1 - 2005/1

UR - http://www.scopus.com/inward/record.url?scp=12844278554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844278554&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.06.005

DO - 10.1016/j.urology.2004.06.005

M3 - Article

C2 - 15667906

AN - SCOPUS:12844278554

VL - 65

SP - 211

EP - 212

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -